MVEC Animation: Thrombosis with Thrombocytopenia Syndrome (TTS) explained
MVEC have created a new animation to help to explain Thrombosis with Thrombocytopenia Syndrome (TTS), a rare and newly identified syndrome which has been reported in people who have received adenoviral vector COVID-19 vaccines such as COVID-19 AstraZeneca and the Johnson & Johnson/Janssen COVID-19 vaccine. This short animation helps to describe what it is, who is at risk and how TTS is diagnosed.
To view the animation and to find out more information on TTS please refer to our immunisation reference page:
MVEC: Thrombosis with Thrombocytopenia
New resource: The MVEC Conversation: Vaccine Confidence
The Melbourne Vaccine Education Centre is excited to announce our latest resource The MVEC Conversation: Vaccine Confidence. This two-part series features vaccine communication experts A/Prof Margie Danchin and Dr Jessica Kaufman and is designed to equip you with the knowledge and practical skills required to confidently address vaccine questions in the community.
पीart 1 – Using both qualitative and quantitative research methods, and applying principles from social and behavioural science, our vaccine experts discuss findings from the COVID-19 Vaccine Preparedness Study. We explore people’s intention to vaccinate and delve into ways in which people can be supported to reach this decision.
Part 2 – We look at the importance of a being a Vaccine Champion and provide you with practical communication strategies to help build vaccine confidence and improve vaccine uptake.
To access this series, please login/register via the MVEC Education Portal.
The Conversation: Should I get my second AstraZeneca dose? Yes, it almost doubles your protection against Delta
With the most recent COVID-19 outbreaks and lockdowns currently going on across the country, there is pressure to speed up Australia’s COVID-19 vaccine roll out.
It is reported that over six million Australians (30% of those eligible) have received their first dose of a COVID-19 vaccine, with 3.8 million of those receiving their first dose as AstraZeneca. While the benefits of vaccination are well known, there are reports of people cancelling their appointments for dose 2 due to concerns about thrombosis with thrombocytopenia syndrome (TTS).
Current UK data suggests that the risk of developing TTS is far lower following dose 2 AstraZeneca, with a rate of approximately 1 in 1.5 million doses.
Completing a 2 dose course of COVID-19 vaccines is important in order to reach optimal levels of protection. One dose of COVID-19 AstraZeneca offers 33% protection against the Delta strain of the virus currently circulating Sydney. This protection almost doubles to 60% once the second dose has been completed.
अधिक पढ़ने के लिए, नीचे दिए गए लिंक का अनुसरण करें:
The Conversation: Should I get my second AstraZeneca dose? Yes, it almost doubles your protection against Delta
Updated immunisation reference page: Vaccine confidence
We have recently updated our Vaccine confidence immunisation reference page to include the latest information and resources available to help address people’s questions and concerns about vaccines.
Our page includes information on how to talk to people who have concerns about vaccines, how to tackle misinformation and how to be a vaccine champion in your workplace or community.
To view this page, please click on the following link:
New immunisation reference page: Myocarditis and pericarditis following mRNA COVID-19 vaccines
Myocarditis is an inflammatory disease of the heart muscle, whilst pericarditis is an inflammatory disease of the lining of the heart muscle. They are rare conditions, most commonly associated with viral infections (including SARS-CoV-2) but can also be triggered by other factors such as medications and autoimmune conditions. Globally, an increased number of cases above an expected population rate of myocarditis and pericarditis have been reported in individuals who have received mRNA COVID-19 vaccines (eg. Comirnaty™ and Moderna).
Our new reference page discusses the temporal association of myocarditis and pericarditis with mRNA COVID-19 vaccination, symptoms, investigations, as well as the implications on future COVID-19 vaccination.
अधिक पढ़ने के लिए नीचे दिए गए लिंक का अनुसरण करें:
MVEC: Myocarditis and pericarditis following mRNA COVID-19 vaccines
New immunisation reference page: Moderna COVID-19 vaccine
Following the announcement by the Australian Government that 25 million doses (as well as additional variant specific versions) of Moderna's COVID-19 vaccine, Elasomeran, had been secured for the Australian population, this vaccine was last week granted provisional determination by the TGA.
Our new reference page explores the various clinical trials involving Elasomeran, as well as details the immunogenicity, efficacy and safety data available for this vaccine.
अधिक पढ़ने के लिए नीचे दिए गए लिंक का अनुसरण करें:
MVEC: Moderna COVID-19 vaccine
TGA grants provisional determination for the Moderna COVID-19 vaccine, Elasomeran
The Therapeutic Goods Administration (TGA) has granted provisional determination to Moderna Australia Pty Ltd for their COVID-19 vaccine candidate, Elasomeran. It is being considered for use in those aged 12 years or older for active immunisation to prevent COVID-19 disease. It is an mRNA vaccine requiring two doses, given 28 days apart.
Granting provisional determination means that Moderna Australia Pty Ltd is now eligible to apply for provisional registration. Following the provisional pathway provides a formal and transparent mechanism for speeding up the registration of promising new medicines with preliminary clinical data.
Provisional determination is only granted once the TGA has considered all eligibility criteria, including evidence of a plan to submit comprehensive clinical data.
You can read the press release from the TGA below:
TGA grants provisional determination for the Moderna COVID-19 vaccine, Elasomeran
For more information on the process of COVID-19 vaccine provisional approval please refer to our reference page:
एमवीईसी: ऑस्ट्रेलिया में सीओवीआईडी-19 वैक्सीन का अनंतिम पंजीकरण
वार्तालाप: ऑस्ट्रेलिया का पहला स्थानीय फाइजर-शैली का COVID वैक्सीन क्या है? और यह हमारी बाहों में कब हो सकता है? एक mRNA विशेषज्ञ बताते हैं
मोनाश विश्वविद्यालय की एक शोध टीम ऑस्ट्रेलिया के पहले एमआरएनए वैक्सीन उम्मीदवार को विकसित करने पर काम कर रही है, जिसके पहले चरण के परीक्षण इस साल अक्टूबर या नवंबर में शुरू होने वाले हैं।
यद्यपि विकास के तहत टीका कोरोनोवायरस के विशिष्ट स्पाइक प्रोटीन के उत्पादन को चिंगारी करने के लिए आरएनए नामक एक आनुवंशिक कोड का उपयोग करके फाइजर और मॉडर्न के टीके के समान सिद्धांतों द्वारा काम करता है, लेकिन प्रमुख उल्लेखनीय अंतर हैं।
सबसे पहले, मोनाश एमआरएनए वैक्सीन कोशिकाओं को स्पाइक प्रोटीन, रिसेप्टर बाइंडिंग डोमेन का एक छोटा सा हिस्सा बनाने के लिए निर्देशित करता है। रिसेप्टर बाइंडिंग डोमेन स्पाइक प्रोटीन की नोक है जो कि वह हिस्सा है जो COVID रोग के नए वेरिएंट बनाने के लिए उत्परिवर्तित हो रहा है। स्पाइक प्रोटीन के इस हिस्से को लक्षित करने से वैरिएंट-विशिष्ट प्रतिक्रियाओं की अनुमति मिलती है, जिसके लिए एक मजबूत नैदानिक आवश्यकता है।
दूसरे, मौजूदा टीकों को वायरस के मूल तनाव पर आधारित किया जाता है जो पहले वुहान में पाया गया था, हालांकि, मोनाश एमआरएनए वैक्सीन को तब से बीटा स्ट्रेन के क्रम में बदल दिया गया है - एक तनाव जो पहली बार दक्षिण अफ्रीका में पाया गया था जिसके लिए मूल से टीके बनाए गए थे। वेरिएंट कम प्रभावी हैं।
यह एमआरएनए टीकों के लचीलेपन पर प्रकाश डालता है, जिसमें दृश्यों को बदला जा सकता है और नए वेरिएंट के लिए अनुकूलित किया जा सकता है जो भविष्य में उभर सकते हैं।
टीके को स्थानीय स्तर पर विकसित करने की योजना पर काम चल रहा है, जो कि mRNA वैक्सीन उत्पादन के लिए ऑस्ट्रेलिया की क्षमता और समग्र रूप से नव विकसित ऑस्ट्रेलियाई आरएनए जैव प्रौद्योगिकी क्षेत्र को विकसित करने की दिशा में एक महत्वपूर्ण कदम है।
अधिक पढ़ने के लिए, नीचे दिए गए लिंक का अनुसरण करें:
वार्तालाप: ऑस्ट्रेलिया का पहला स्थानीय फाइजर-शैली का COVID वैक्सीन क्या है? और यह हमारी बाहों में कब हो सकता है? एक mRNA विशेषज्ञ बताते हैं
Healthed Going Viral Podcast featuring A/Prof Nigel Crawford
Associate Professor Nigel Crawford is interviewed by Dr David Lim, GP and Medical Educator on Healthed Australia’s Going Viral podcast. In this podcast, Nigel discusses the clinical features of Thrombosis with thrombocytopenia syndrome (TTS) and provides an approach for diagnosing and managing it.
You can listen to the podcast here:
Healthed Australia: Going Viral Podcast Episode 157: AZ Clots – Are you missing it?
PHN Webinar: Primary care identification and management of thrombosis with thrombocytopenia syndrome (TTS)
The PHN will be hosting a webinar for GPs on Wednesday 30 June featuring a panel of expert speakers including MVEC’s A/Prof Nigel Crawford. The topic for the webinar is Primary care identification and management of thrombosis with thrombocytopenia syndrome (TTS) and will cover:
- pathogenesis
- latest incidence rates in age groups
- incidence of different TTS clinical types
- presentation and identification
- GP management guidelines.
Further information and details on registration can be found via the link below: